Covaxin india News

NITI Aayog Member (Health) V K Paul noted that there is a risk even after taking vaccination "We stress people to follow COVID appropriate behaviour even after taking the vaccination," he said

In the third phase of the coronavirus vaccination drive which begins from March 1, the government is aiming to expand the vaccination drive to the general public of the nation. People with co-morbid conditions will need to carry a medical certificate to receive the vaccination.

NITI Aayog has promulgated a price range of Rs 300-500 which the private hospitals can charge for the two COVID-19 vaccines. The government has been procuring SII's Covishield for around Rs 210 per dose while the cost of Covaxin is around Rs 290 for a shot.

The NITI Aayog has promulgated a price range of Rs 300-500 for two Covid vaccines that would be available for the priority group at private facilities. In the third phase of vaccination set to begin from March 1 Covid vaccines will be available in private hospitals as well.

The indigenous vaccine is developed and manufactured at Bharat Biotech’s Biosafety Level-3 biocontainment facility. The vaccine is only for those above 18 years, not for children as the research has to be done in the case of covid vaccine for children. Covaxin may be priced near Rs 1,000 when it reaches to the market.

Union Health Minister Harsh Vardhan on December 19 had said that country`s scientists and health experts have worked on the development of an indigenous vaccine In the upcoming six to seven months, India will have the capacity to inoculate about 30 crore people The six vaccine candidates which are in various stages of the clinical trial are - Covishield, Covaxin, ZyCoV-D, Sputnik V, NVX-CoV2373

The Drug Controller General of India has allowed Bharat Biotech India (BBIL) to conduct human clinical trials for ‘COVAXIN’, a potential COVID-19 vaccine. The human clinical trials will start across India in July 2020. If it emerges successful, COVAXIN will be available by year’s end.